Logo image of FTRE

FORTREA HOLDINGS INC (FTRE) Stock Fundamental Analysis

NASDAQ:FTRE - Nasdaq - US34965K1079 - Common Stock - Currency: USD

5.45  -0.01 (-0.18%)

After market: 5.45 0 (0%)

Fundamental Rating

3

Taking everything into account, FTRE scores 3 out of 10 in our fundamental rating. FTRE was compared to 55 industry peers in the Life Sciences Tools & Services industry. Both the profitability and financial health of FTRE have multiple concerns. FTRE is valued quite cheap, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

2

1. Profitability

1.1 Basic Checks

FTRE had positive earnings in the past year.
In the past year FTRE had a positive cash flow from operations.
In multiple years FTRE reported negative net income over the last 5 years.
FTRE had a positive operating cash flow in each of the past 5 years.
FTRE Yearly Net Income VS EBIT VS OCF VS FCFFTRE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 0 200M -200M

1.2 Ratios

FTRE has a Return On Assets of -25.32%. This is in the lower half of the industry: FTRE underperforms 70.91% of its industry peers.
FTRE's Return On Equity of -92.04% is on the low side compared to the rest of the industry. FTRE is outperformed by 76.36% of its industry peers.
Industry RankSector Rank
ROA -25.32%
ROE -92.04%
ROIC N/A
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
FTRE Yearly ROA, ROE, ROICFTRE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -10 -20

1.3 Margins

FTRE has a worse Gross Margin (20.21%) than 81.82% of its industry peers.
FTRE's Gross Margin has been stable in the last couple of years.
FTRE does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 20.21%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
FTRE Yearly Profit, Operating, Gross MarginsFTRE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 10 -10 20

1

2. Health

2.1 Basic Checks

FTRE does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, FTRE has more shares outstanding
Compared to 1 year ago, FTRE has an improved debt to assets ratio.
FTRE Yearly Shares OutstandingFTRE Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 20M 40M 60M 80M
FTRE Yearly Total Debt VS Total AssetsFTRE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 1B 2B 3B 4B

2.2 Solvency

FTRE has an Altman-Z score of 0.44. This is a bad value and indicates that FTRE is not financially healthy and even has some risk of bankruptcy.
FTRE's Altman-Z score of 0.44 is on the low side compared to the rest of the industry. FTRE is outperformed by 69.09% of its industry peers.
FTRE has a debt to FCF ratio of 8.36. This is a slightly negative value and a sign of low solvency as FTRE would need 8.36 years to pay back of all of its debts.
FTRE has a Debt to FCF ratio of 8.36. This is comparable to the rest of the industry: FTRE outperforms 56.36% of its industry peers.
FTRE has a Debt/Equity ratio of 1.22. This is a high value indicating a heavy dependency on external financing.
Looking at the Debt to Equity ratio, with a value of 1.22, FTRE is doing worse than 81.82% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 1.22
Debt/FCF 8.36
Altman-Z 0.44
ROIC/WACCN/A
WACC7.15%
FTRE Yearly LT Debt VS Equity VS FCFFTRE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 1B 2B 3B

2.3 Liquidity

FTRE has a Current Ratio of 0.97. This is a bad value and indicates that FTRE is not financially healthy enough and could expect problems in meeting its short term obligations.
FTRE has a worse Current ratio (0.97) than 87.27% of its industry peers.
A Quick Ratio of 0.97 indicates that FTRE may have some problems paying its short term obligations.
The Quick ratio of FTRE (0.97) is worse than 81.82% of its industry peers.
Industry RankSector Rank
Current Ratio 0.97
Quick Ratio 0.97
FTRE Yearly Current Assets VS Current LiabilitesFTRE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 200M 400M 600M 800M 1B

3

3. Growth

3.1 Past

The earnings per share for FTRE have decreased strongly by -543.42% in the last year.
The Revenue for FTRE has decreased by -10.69% in the past year. This is quite bad
Measured over the past years, FTRE shows a decrease in Revenue. The Revenue has been decreasing by -4.10% on average per year.
EPS 1Y (TTM)-543.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
Revenue 1Y (TTM)-10.69%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%-1.63%

3.2 Future

The Earnings Per Share is expected to grow by 40.35% on average over the next years. This is a very strong growth
Based on estimates for the next years, FTRE will show a small growth in Revenue. The Revenue will grow by 1.93% on average per year.
EPS Next Y36.58%
EPS Next 2Y53.03%
EPS Next 3Y54.55%
EPS Next 5Y40.35%
Revenue Next Year-7.03%
Revenue Next 2Y-2.94%
Revenue Next 3Y-0.61%
Revenue Next 5Y1.93%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
FTRE Yearly Revenue VS EstimatesFTRE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 1B 2B 3B
FTRE Yearly EPS VS EstimatesFTRE Yearly EPS VS EstimatesYearly EPS VS Estimates 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0.5 1 1.5 2

8

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings ratio is 13.63, which indicates a correct valuation of FTRE.
Compared to the rest of the industry, the Price/Earnings ratio of FTRE indicates a rather cheap valuation: FTRE is cheaper than 96.36% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of FTRE to the average of the S&P500 Index (26.34), we can say FTRE is valued slightly cheaper.
A Price/Forward Earnings ratio of 6.84 indicates a rather cheap valuation of FTRE.
Compared to the rest of the industry, the Price/Forward Earnings ratio of FTRE indicates a rather cheap valuation: FTRE is cheaper than 98.18% of the companies listed in the same industry.
FTRE is valuated cheaply when we compare the Price/Forward Earnings ratio to 22.19, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 13.63
Fwd PE 6.84
FTRE Price Earnings VS Forward Price EarningsFTRE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Based on the Price/Free Cash Flow ratio, FTRE is valued cheaper than 100.00% of the companies in the same industry.
Industry RankSector Rank
P/FCF 3.4
EV/EBITDA N/A
FTRE Per share dataFTRE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
FTRE's earnings are expected to grow with 54.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)0.37
PEG (5Y)N/A
EPS Next 2Y53.03%
EPS Next 3Y54.55%

0

5. Dividend

5.1 Amount

No dividends for FTRE!.
Industry RankSector Rank
Dividend Yield N/A

FORTREA HOLDINGS INC

NASDAQ:FTRE (6/18/2025, 8:00:00 PM)

After market: 5.45 0 (0%)

5.45

-0.01 (-0.18%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryLife Sciences Tools & Services
Earnings (Last)05-12 2025-05-12/bmo
Earnings (Next)08-11 2025-08-11/bmo
Inst Owners102.48%
Inst Owner Change-0.53%
Ins Owners0.22%
Ins Owner Change26.35%
Market Cap493.23M
Analysts51.76
Price Target6.1 (11.93%)
Short Float %14.93%
Short Ratio4.49
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)37.49%
Min EPS beat(2)-51.68%
Max EPS beat(2)126.66%
EPS beat(4)1
Avg EPS beat(4)-17.4%
Min EPS beat(4)-134.75%
Max EPS beat(4)126.66%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)1.07%
Min Revenue beat(2)-2.83%
Max Revenue beat(2)4.96%
Revenue beat(4)1
Avg Revenue beat(4)-1.4%
Min Revenue beat(4)-5.76%
Max Revenue beat(4)4.96%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-21.35%
PT rev (3m)-72.45%
EPS NQ rev (1m)35.66%
EPS NQ rev (3m)-77.03%
EPS NY rev (1m)0%
EPS NY rev (3m)-64.82%
Revenue NQ rev (1m)0.45%
Revenue NQ rev (3m)-6.26%
Revenue NY rev (1m)0.51%
Revenue NY rev (3m)-3.06%
Valuation
Industry RankSector Rank
PE 13.63
Fwd PE 6.84
P/S 0.18
P/FCF 3.4
P/OCF 3
P/B 0.57
P/tB N/A
EV/EBITDA N/A
EPS(TTM)0.4
EY7.34%
EPS(NY)0.8
Fwd EY14.61%
FCF(TTM)1.6
FCFY29.42%
OCF(TTM)1.81
OCFY33.29%
SpS29.68
BVpS9.49
TBVpS-11.44
PEG (NY)0.37
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -25.32%
ROE -92.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 20.21%
FCFM 5.4%
ROA(3y)-1.75%
ROA(5y)-2.26%
ROE(3y)-6.6%
ROE(5y)-5.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.07%
GM growth 5YN/A
F-Score5
Asset Turnover0.86
Health
Industry RankSector Rank
Debt/Equity 1.22
Debt/FCF 8.36
Debt/EBITDA N/A
Cap/Depr 23.04%
Cap/Sales 0.71%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.97
Quick Ratio 0.97
Altman-Z 0.44
F-Score5
WACC7.15%
ROIC/WACCN/A
Cap/Depr(3y)43.05%
Cap/Depr(5y)33.05%
Cap/Sales(3y)1.37%
Cap/Sales(5y)1.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-543.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%150%
EPS Next Y36.58%
EPS Next 2Y53.03%
EPS Next 3Y54.55%
EPS Next 5Y40.35%
Revenue 1Y (TTM)-10.69%
Revenue growth 3Y-4.1%
Revenue growth 5YN/A
Sales Q2Q%-1.63%
Revenue Next Year-7.03%
Revenue Next 2Y-2.94%
Revenue Next 3Y-0.61%
Revenue Next 5Y1.93%
EBIT growth 1Y-492.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-2.71%
EBIT Next 3Y9.38%
EBIT Next 5Y9.67%
FCF growth 1Y85.25%
FCF growth 3Y18.31%
FCF growth 5YN/A
OCF growth 1Y56.06%
OCF growth 3Y15.67%
OCF growth 5YN/A